Information Provided By:
Fly News Breaks for November 5, 2019
Nov 5, 2019 | 16:05 EDT
Chardan analyst Geulah Livshits initiated coverage of Rocket Pharmaceuticals with a Buy rating and $30 price target citing the potential of its blended ex vivo/in vivo gene therapy pipeline. The analyst said Rocket is rapidly advancing its pipeline with 4 company sponsored INDs cleared within the last 12 months to provide transformative treatments for patients with rare monogenic diseases and shareholder value through inflection points.